Table 3.
Immunogenicity in the ADACCESS study [20]
| TP1 (randomization to Week 17) | TP2 + EP (Week 17 to Week 51) | |||||
|---|---|---|---|---|---|---|
| SDZ-ADL (n = 231) | REF-ADL (n = 234) | SDZ-ADL → REF-ADL (n = 63) | Continued SDZ-ADL (n = 126) | REF-ADL → SDZ-ADL (n = 63) | Continued REF-ADL (n = 127) | |
| Negative | 139/220 (63.2) | 145/220 (65.9) | 32/60 (53.3) | 79/123 (64.2) | 37/61 (60.7) | 67/122 (54.9) |
| Positive | 81/220 (36.8) | 75/220 (34.1) | 28/60 (46.7) | 44/123 (35.8) | 24/61 (39.3) | 55/122 (45.1) |
| Neutralizing | 65/81 (80.2) | 60/75 (80.0) | 21/28 (75.0) | 38/44 (86.4) | 24/24 (100.0) | 47/55 (85.5) |
Figure reproduced courtesy of Blauvelt A, et al. Br J Dermatol. 2018;179:623–631
EP extension period, REF-ADL reference adalimumab, SDZ-ADL Sandoz biosimilar adalimumab, TP treatment period